The Cognitive Impairment Associated With Schizophrenia (CIAS) drugs in development market research report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cognitive Impairment Associated With Schizophrenia (CIAS). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Cognitive Impairment Associated With Schizophrenia (CIAS) by 14 companies/universities/institutes. The top development phase for Cognitive Impairment Associated With Schizophrenia (CIAS) is phase i with six drugs in that stage. The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline products market are: Boehringer Ingelheim International, Pfizer and INVENT Pharmaceuticals.

The key targets in the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline products market include Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7), Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9), and Soluble Guanylate Cyclase (sGC or EC 4.6.1.2).

The key mechanisms of action in the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline product include Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Inhibitor with two drugs in Phase III. The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline products include one routes of administration with the top ROA being Oral and one key molecule types in the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline products market including Small Molecule.

Cognitive Impairment Associated With Schizophrenia (CIAS) overview

Cognitive functioning is moderately to severely impaired in patients with schizophrenia. Symptoms of cognitive impariment associated with schizophrenia (CIAS) include poor executive functioning, inability to sustain attention, and problems with working memory. Predisposing factors include family history, age, and autoimmune diseases. Treatment includes antipsychotic medications.

For a complete picture of Cognitive Impairment Associated With Schizophrenia (CIAS)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.